Patrick Daly

Patrick Daly is an Assistant Editor at AMC Media Group.

Articles by Patrick Daly

Patrick DalyFollicular Lymphoma | January 7, 2025
Data support rituximab over watchful waiting in front-line therapy for low-tumor-burden follicular lymphoma, study concludes.
Read More
Patrick DalyAcute Myeloid Leukemia | December 23, 2024
Ziftomenib, venetoclax, and azacitadine is an close to an all-oral regimen for relapsed/refractory acute leukemias.
Patrick DalyAcute Myeloid Leukemia | December 23, 2024
The benefit of alternating venetoclax regimens was shown in patients with AML and certain AML subgroups.
Patrick DalyAcute Lymphoblastic Leukemia | December 23, 2024
Continued treatment and follow-up of patients after the interim analysis demonstrate the durability of response to revumenib.
Patrick DalyAcute Myeloid Leukemia | December 23, 2024
The confirmed complete response rate of ziftomenib with chemotherapy was high in patients with AML subtypes.
Patrick DalyMeeting News | December 20, 2024
Early signs of clinical activity have been shown in a phase I/II study of tagraxofusp/decitabine in MDS and CMML.
Patrick DalyMeeting News | December 20, 2024
Mature data of three immunotherapy-based hypomethylating agent combinations were presented at ASH.
Patrick DalyAcute Myeloid Leukemia | January 17, 2025
Interim results suggest acceptable safety and high efficacy of CPX-351 plus ivosidenib.
Patrick DalyAcute Myeloid Leukemia | December 20, 2024
High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic SCT.
Patrick DalyTransplantation & Cellular Therapy | December 7, 2024
Robust responses with favorable safety has been demonstrated with tisagenlecleucel in relapsed or refractory Fl.
Patrick DalyTransplantation & Cellular Therapy | December 7, 2024
Favorable preclinical outcomes were demonstrated with VX765 treatment.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
Tapotoclax was safe and may warrant consideration in combination with other therapies in MDS post-HMA failure.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
ESAs had a high rate of failure among patients with lower-risk MDS and often continued treatment despite failure.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
Oral azacitidine plus cedazuridine achieved pharmacokinetic equivalence to subcutaneous azacitidine in MDS and MPN.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
Retrospective analysis shows that AML treatment strategies are effective for patients with MDS or CMML with NPM1 mutations.
Patrick DalyChronic Lymphocytic Leukemia | November 27, 2024
Anti-CD19 CAR T-cell therapy appeared to cure a significant number of patients with relapsed or refractory CLL.
Saad Z. Usmani, MD, MBA, FACPThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Patrick DalyAcute Myeloid Leukemia | November 12, 2024
Pivekimab sunirine showed single-agent activity across multiple doses in the treatment of patients with AML.
Patrick DalyMeeting News | November 4, 2024
Isolating CD34-positive samples from patients with MDS was better able to detect molecular relapse.
Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.